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Several prospective studies with invasive carcinoma as endpoint have supported Human Papillomavirus as a cause of cervical
carcinoma. However, the largest study used seroepidemiology and did not analyse presence of Human Papillomavirus DNA in
the subsequent tumour. Linkage of serum bank registries and cancer registries had identiﬁed 196 women with a registered
cervical carcinoma after donation of a serum sample. For the present study, biopsies for 127 cases could be located, veriﬁed
to contain invasive carcinoma and be ampliﬁed by PCR. Three control women who had remained alive and without cervical
carcinoma during an equal length of follow-up had been matched to each of the case women and tested for HPV antibodies.
Presence of Human Papillomavirus DNA in the tumours was analysed by general primer and type speciﬁc PCR. HPV16-
seropositive women had a relative risk of 4.4 (95% CI: 2.2–8.8) to develop cervical carcinoma carrying HPV16 DNA. By
contrast, there was no excess risk for Human Papillomavirus 16-seropositive women to develop cervical carcinoma devoid of
HPV16 DNA. Prediagnostic HPV16 seropositivity was strongly correlated with later HPV16 DNA positivity of the tumour
(P50.001) and prediagnostic HPV18 seropositivity correlated with HPV18 DNA in the tumour (P50.03). The link between
prediagnostic seropositivity and type of viral DNA in the cancer implies that the carcinogenic effect of infection with these
viruses is dependent on persistent presence of type-speciﬁc viral DNA.
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The most important risk factor for development of cervical carci-
noma is infection with the oncogenic types of human
papillomavirus (HPV). A series of cross-sectional case-control
studies, based both on HPV DNA testing of tumours (Walboomers
et al, 1999), measurement of serum HPV antibodies (Dillner et al,
1995), or both (Nonnenmacher et al, 1995; de Sanjose et al, 1996)
have found a consistent and strong association between HPV and
cervical carcinoma.
That the association between HPV and cervical carcinoma is
causal is supported also by prospective studies, both with cervical
intraepithelial neoplasia (Koutsky et al, 1992; Chua et al, 1996)
and invasive cervical carcinoma as the end-point (Lehtinen et al,
1996; Shah et al, 1997; Vonka et al, 1999; Wallin et al, 1999).
However, most prospective studies are based on limited numbers
of cases. The largest study to date is a seroepidemiological study
that contained 182 cases (Dillner et al, 1997). However, prediag-
nostic seropositivity and type of HPV DNA in subsequently
occurring invasive carcinoma has not been previously performed.
Combining seroepidemiological studies with HPV DNA analyses
in prospective studies could be important for several reasons. For
example, there are indications that prior or ongoing HPV infec-
tions may interact in a complex fashion in cervical carcinogenesis
(Luostarinen et al, 1999; Silins et al, 1999). By comparing prediag-
nostic assessment of virus exposure with presence of virus DNA in
the tumour, it could be possible to infer whether type-speciﬁc
persistence of HPV is the predominant mode of action of HPV
in cervical carcinogenesis or whether previous infections with
different HPV types also could have an effect on the cervical carci-
noma risk. Furthermore, although a series of validation studies
have indicated HPV type-speciﬁcity of HPV serology, within-study
validation of the test performance is optimal. In order to provide a
more informative and reliable prospective study on the effect of
HPV infection on the subsequent risk of cervical carcinoma, we
expanded a previous longitudinal seroepidemiological study with
HPV DNA analyses of subsequent carcinomas. For improved accu-
racy, the histopathological diagnoses were also re-evaluated.
SUBJECTS AND METHODS
Subjects
The study base consists of about 550000 healthy women who
donated blood samples to three population-based serum banks in
Norway, Finland and Sweden (Table 1). The Janus project in
Norway was initiated in 1973 to search in the premorbidity sera
for changes indicative of chronic disease development at early
stages and contains 425000 blood samples from 294000 subjects
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www.bjcancer.com(stored at 7258C). This project was conducted in two phases.
Phase I was conducted during the period from 1974 through
1978 and enrolled 29000 subjects residing in one of three Norwe-
gian counties (Finnmark, Sogn og Fjordane, or Oppland). Phase II
was conducted during the period from 1986 through 1991
throughout Norway and enrolled 116000 subjects. Whereas phase
I enrolled subjects of a wide age range, phase II primarily focused
on 40- to 42-year-old subjects. The response rate to the popula-
tion-based invitation to participate was 85% in phase I and 75%
in phase II (Jellum et al, 1995).
The Finnish Maternity Cohort contains blood samples from
about 98% of all pregnant women in Finland. The samples are
taken at the Finnish maternity clinics from women during early
pregnancy (ﬁrst trimester) for screening for congenital infections.
Enrolment started in 1983 and is still ongoing. In 1993, the bank
contained 710000 samples obtained from 390000 women (stored
at 7258C) (Dillner et al, 1997).
The Va ¨sterbotten project (Sweden) was initiated in a county in
northern Sweden in 1986 and is still ongoing. In 1993, it contained
blood samples obtained from about 15000 female residents (stored
at 7808C). Each year all residents of ages 30, 40, 50, and 60 years
are invited by letter to participate in a health-promoting project,
including the donation of biologic samples for medical research.
The response rate is usually about 65% (Dillner et al, 1997).
Women who had donated serum at least 2 weeks prior to a
cervical malignant tumour diagnosis were identiﬁed by linkage of
the data ﬁles of the serum banks with the nation-wide cancer regis-
tries in Norway, Finland and Sweden, using the personal
identiﬁcation numbers. Analysis of the HPV serology in the present
study by lag time in tertiles (512, 12–59 and 459 months
between sampling and diagnosis) found no statistically signiﬁcant
evidence on dependence of lag time (Dillner et al, 1997). Notiﬁca-
tion of new cancer cases is compulsory in the three countries, and
multiple data sources ensure almost 100% completion of the cancer
registries (Engeland et al, 1993). From start-up of the respective
serum banks until the linkages done in 1994, invasive cervical
carcinoma had been diagnosed in 196 women with a serum speci-
men stored. In addition, 24 women who developed cervical
malignant tumour had been sampled, but had no longer had serum
stored.
Of these, 10 cases were excluded: four who had a lag time
between enrolment and diagnosis of less than 2 weeks, two for
whom the serum samples were not located, two cases for whom
the available biopsies had been taken 2 years after the ﬁrst diagno-
sis of invasive carcinoma was made and two cases where the blocks
were not correctly located. From the rest we were able to retrieve
histological material from 153. Twenty-six of these were excluded:
one with an unclassiﬁable malignant tumour, one small cell carci-
noma, two cases with benign histology from another organ, 10
cases with tumour of noninvasive histology (carcinoma in situ),
six cases that could not be ampliﬁed by PCR in the HLA test, ﬁve
cases with an empty control slide and one case where the PCR
detection for HPV was done on incorrect material. The registry
linkage is the same as in the previous study (Dillner et al, 1997),
but more cases are excluded due to the fact that retrieval of
tumour specimens, ampliﬁability in PCR and veriﬁed histopatholo-
gical diagnosis on review was also required in this study.
The distribution of the different types of cervical carcinoma and
age at diagnosis of the remaining 127 cases are shown in Table 2.
More than two thirds of the patients developed cervical carcinoma
before the age of 50 years and more than 10% were younger than
35 years. If more than one prediagnostic serum sample was avail-
able, the ﬁrst (oldest) sample was chosen. For each case patient,
three control subjects who had remained alive and free of cervical
malignant tumour for an equal length of follow-up were selected
and individually matched for sex, age at serum sampling (+2
years), length of serum storage (+2 months), country, and in
Norway also for county of residence. If three control subjects per
case patient fulﬁlling the matching criteria could not be found,
the matching criteria on age at serum sampling and length of
serum storage were widened in successive steps of 1 year of age
and 1 month of storage until three control subjects were found.
The mean difference in age was 1.5 years. The maximum age
discrepancy (4 years) was present for three of 376 control subjects.
The mean difference in time of sampling was 2.1 months, with
none of the control subjects differing by more than 6 months.
The prospective study was approved by the Data Protection/Insti-
tutional review boards of the respective countries.
Laboratory methods
All laboratory analyses were performed on coded specimens.
HPV serology
Capsids containing both the L1 and L2 capsid proteins of HPV
type 16 (clone 114/K), 18, or 33 or of bovine papillomavirus
(BPV) type 1 generated in insect cells by use of recombinant bacu-
loviruses were the kind gift of Dr John T Schiller, National Cancer
Institute, USA and Dr Martin Sapp, University of Mainz, Germany.
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Table 1 Distribution of cases and serum sample controls (numeric) with cervical carcinoma by study
characteristics and serum bank
Janus serum The Finnish maternity The Va ￿sterbotten
bank
a cohort project
b All cohorts
Period of serum sampling 1974–78 & 1986–91 1983– 1986– 1974–
No of female donors 145 000 390 000 15 000 550 000
Number of cases n=93 n=31 n=3 n=127
(Controls) (279) (88) (9) (376)
Age at diagnosis:
23–29 – 8 – 8
30–34 3 6 – 9
35–39 6 8 – 14
40–44 27 7 2 36
45–49 22 2 – 24
50–54 15 – – 15
55–59 10 – – 10
60–64 10 – 1 11
aJanus serum bank/several counties in Norway.
bCounty of Va ￿sterbotten.
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dard enzyme-linked immunosorbent assay method employing a
monoclonal antibody against human immunoglobulin G (IgG) (g
chain) and a goat anti-mouse IgG horseradish peroxidase conjugate
(Dillner et al, 1995). For each serum, we calculated the difference
in optical density obtained with plates coated with intact HPV
capsids and plates coated with control antigen (disrupted BPV
capsids). The cutoff levels for determining seropositivity from
continuous values were established in previous work (Andersson-
Ellstro ¨m et al, 1996), which had determined that a cutoff level of
0.100 absorbance unit was able to distinguish HPV-infected women
from virgin women. Our previous report had used two alternative
cut-off level designations and had found little differences in results
(Dillner et al, 1996) and in this study only the 0.100 cutoff was
used. All assays were performed at least twice. The proportions
of samples with discrepant results upon repeated analysis were
1.9% for HPV 16, 7.2% for HPV 18, and 4.3% for HPV 33. Discre-
pancies were resolved by multiple repeat analyses. A panel of serum
samples from virginal women was analysed in parallel and no HPV
antibodies could be found (Andersson-Ellstro ¨m et al, 1996).
Histologic review
All histologic specimens were reviewed by two of the authors, E
Sigstad and V Abeler, who were blinded to registered diagnoses
and to all other results in the study database. The tumours were
classiﬁed and graded according to the World Health Organisation
(WHO) histologic typing of female genital tract tumours (WHO,
1975). When possible, the tumour was classiﬁed on the ﬁrst biopsy.
When the ﬁrst biopsy was of bad quality or the material was too
small, the classiﬁcation was done on the best-preserved specimen.
All slides from each case were stained with standard haematoxylin
and eosin staining. In some cases preoperative irradiation had
affected the cervical tumour to the extent that classiﬁcation was
difﬁcult.
HPV DNA detection
DNA was extracted from parafﬁn-embedded tissue as described by
Shibata et al (1988) but instead of boiling, the tissue sections were
treated with proteinase K and incubated at 558C overnight. Protei-
nase K was then inactivated at 958C for 15 min. The microtome
was cleaned in xylene and a new blade was used between each
block. Sections from empty blocks were used as a contamination
control in-between each specimen.
HPV–PCR was performed with the L1 consensus primers
Gp5+/6+, giving a PCR product of 150 bp (de Roda Husman et
al, 1995). Ampliﬁcation was carried out for 40 cycles in a Perkin
Elmer Cetus thermal cycler. Each cycle of ampliﬁcation consisted
of 1 min of denaturation at 948C, 1 min of annealing at 438C,
and 1 min of polymerisation at 728C. The ﬁrst cycle was preceded
by 7 min denaturation and the last cycle was extended by a 7 min
elongation step at 728C. The HeLa cell line was used as a positive
control and H2O as a negative control in each PCR assay. The
quality of the DNA extracts was tested by ampliﬁcation of HLA-
DQ1 with the primers GH26/GH27, giving a PCR product of
250 bp. PCR products were controlled by gel electrophoresis
(10% polyacrylamide), followed by transillumination with UV-
light. Specimens not giving a DQA1 product, but giving a Gp5+/
6+ product, went to further examination, while specimens not
giving products were excluded from the HPV–PCR.
HPV DNA positive cases were typed with E6 and E7 type-speci-
ﬁc primers for HPV16, 18 and 33 (Hagmar et al, 1992; Lie et al,
1999). All HPV DNA negative cases were also tested with the
HPV16 and 18 primers to control for possible false negatives due
to deletion in the L1 region after integration of HPV.
Statistical analyses
The odds ratios (ORs) and their 95% conﬁdence intervals (CI)
were estimated by conditional logistic regression (Breslow and
Day, 1980) with the EGRET software (Cytel Software Corporation,
Cambridge, MA, USA). If the asymptotic model did not converge,
analyses were conducted with the exact inference methods (Mehta
et al, 1985) for contingency tables implemented in the EPIXACT
software (Cytel Software Corporation, Cambridge, MA, USA).
Fisher‘s exact test tested for equity between proportions. A two-
tailed P value of less than 0.05 indicated statistical signiﬁcance.
RESULTS
HPV16 seropositive women had an increased risk to develop inva-
sive cervical carcinoma compared to HPV16 seronegative women
(OR=2.4; 95% CI 1.4–4.3), which was a ﬁnding similar to our
previous report from the same material (Dillner et al, 1997). The
risk to develop squamous cell carcinoma was somewhat higher
(odds ratio=2.8; 95% CI 1.6–5.0) (Table 3). HPV18 and HPV33
seropositive women both had two-fold relative risks to develop
cervical carcinoma. Because of small numbers, the relative risk of
HPV18 seropositive women to develop cervical adenocarcinoma
could not be estimated, but the risk was highly signiﬁcantly
increased (Table 3). Joint seropositivity for both HPV16 and 18
further increased the risk for invasive cervical carcinoma
(OR=3.5; 95% CI: 1.6–7.6).
HPV16-seropositive women were at a 4.4-fold risk to develop
HPV16 DNA carrying invasive cervical cancer, but they had no
excess risk to develop cervical carcinoma containing other HPV
types or carcinomas negative for HPV DNA by PCR (Table 4).
Restricting the analysis to cervical squamous cell carcinoma gave
similar results (Table 5).
Among 29 HPV16 seropositive women who developed invasive
cervical carcinoma, 26 had HPV16 DNA positive tumours whereas
46 of 96 HPV16 seronegative women developing carcinoma had
HPV16 DNA positive tumours (P50.001). For squamous cell
carcinoma the corresponding ﬁgures for HPV16 DNA positivity
were 26 of 29 HPV16 seropositive, and 42 of 76 HPV16 seronega-
tive women, respectively (P50.001).
HPV18 DNA positivity was found in six of 18 HPV18 seroposi-
tive women with invasive cervical carcinoma and in 14 of 110
HPV18 seronegative women (P=0.027).
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Table 2 Age at diagnosis of the different histological types of cervical carcinoma
Age at diagnosis/serum sampling
Histology 23–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 Total
Squamous cell carcinoma 8 8 12 25 24 13 8 9 107
Adenocarcinoma – 1 2 10 – 1 1 1 16
Adenosquamous carcinoma – – – 1 – – 1 – 2
Undifferentiated carcinoma – – – – – 1 – 1 2
Total 8 9 14 36 24 15 10 11 127
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 175–180Only one woman had a cervical carcinoma biopsy containing
HPV33. She was HPV33 seronegative in her prediagnostic serum
sample. In contrast to the results for HPV16 and HPV18,
HPV33 seropositivity was associated with increased risk to develop
carcinoma containing other viral types: A two-fold relative risk to
develop HPV16 DNA positive cancers was seen (Table 4).
DISCUSSION
This prospective and population-based study enabled an investiga-
tion of the natural history of cervical carcinoma with regards to
HPV exposure and to intermittent and persistent infections with
HPV. The present study advances previous studies on prediagnostic
seropositivity in that it also correlates seropositivity to HPV DNA
positivity in specimens from parafﬁn blocks histologically shown to
contain a subsequently developed invasive cervical carcinoma.
Histopathological specimens were provided from 153 cases out of
196 women reported with a diagnosis of cervical carcinoma after
enrollment. Re-examination of these cases by two of the authors
conﬁrmed the diagnosis of cervical carcinoma in most cases.
However, as many as 26 cases (17%) were excluded. Twelve of
these (7.8%) were excluded because the diagnosis of invasive cervi-
cal carcinoma was not conﬁrmed. This is in line with what is
shown by others (Chua et al, 1996) and demonstrates the impor-
tance of histological re-examination in registry-based studies.
There were signiﬁcantly more HPV DNA positive tumours
among the seropositive compared to the seronegative cases. The
results conﬁrm earlier studies demonstrating the correlation
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Table 3 Odds ratio (OR) with 95% conﬁdence intervals (CI) for invasive cervical carcinoma (ICC), cervical squamous cell carcinoma (SCC), and ade-
nocarcinoma (AC) related to seropositivity for human papillomavirus types 16, 18 and 33
ICC SCC AC
No. of No. of No. of
Seropositivity cases controls OR 95% CI cases controls OR 95% CI cases controls OR 95% CI
HPV 16 No 96 330 1 76 275 1 16 43 1
c-o=100 Yes 28 41 2.4 (1.4, 4.3) 28 37 2.8 (1.6, 5.0) – 4 – (74.8)
a
HPV 18 No 109 342 1 93 284 1 12 47 1
Yes 18 30 1.9 (1.0, 3.6) 14 29 1.5 (0.7, 3.0) 4 – inf (2.0, inf)
a
HPV 33 No 104 330 1 85 274 1 15 44 1
Yes 23 42 1.8 (1.0, 3.2) 22 39 1.9 (1.0, 3.4) 1 3 1.0 (0.1, 9.6)
aExact inference methods for 26k tables.
Table 4 Odds ratio (OR) with 95% conﬁdence intervals (CI) for invasive cervical carcinoma related to seropositivity for human papillomavirus types 16,
18 and 33 among HPV DNA positives and negatives (HPV types 16, 18, 33)
HPV 16 DNA positive HPV 18 DNA positive Other HPV DNA/neg
No. of No. of No. of
Seropositivity cases controls OR 95% CI cases controls OR 95% CI cases controls OR 95% CI
HPV 16 No 46 188 1 17 50 1 33 95 1
c-o=100 Yes 26 26 4.4 (2.2, 8.8) 2 6 0.9 (0.2, 5.0) 1 9 0.3 (0.0, 2.5)
HPV 18 No 66 196 1 14 56 1 30 93 1
Yes 7 18 1.1 (0.5, 2.8) 6 1 17 (2.1, 140) 5 11 1.5 (0.4, 5.4)
HPV 33 No 58 191 1 19 53 1 28 89 1
Yes 15 23 2.1 (1.0, 4.4) 1 4 0.7 (0.1, 6.2) 7 15 1.6 (0.5, 4.8)
Table 5 Odds ratio (OR) with 95% conﬁdence intervals (CI) for cervical squamous cell carcinoma related to seropositivity for human papillomavirus types
16, 18 and 33 among HPV DNA positives, and HPV DNA negatives (HPV types 16, 18 and 33)
HPV 16 DNA positive HPV 18 DNA positive Other HPV DNA/neg
No. of No. of No. of
Seropositivity cases controls OR 95% CI cases controls OR 95% CI cases controls OR 95% CI
HPV 16 No 42 179 1 7 21 1 27 78 1
c-o=100 Yes 26 24 4.9 (2.4, 9.9) 2 5 1.1 (0.2, 6.5) 1 8 0.3 (0.0, 2.9)
HPV 18 No 62 186 1 8 26 1 24 75 1
Yes 7 17 1.2 (0.5, 3.0) 2 1 5.3 (0.5, 59) 5 11 1.5 (0.4, 5.4)
HPV 33 No 54 180 1 10 25 1 22 72 1
Yes 15 23 2.1 (1.0, 4.4) – 2 – (7, 13)
a 7 14 1.8 (0.6, 5.6)
aExact inference methods for 26k tables.
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British Journal of Cancer (2002) 87(2), 175–180 ã 2002 Cancer Research UKbetween infection with the investigated types of HPV16 and
HPV18 and an increased risk of developing cervical carcinoma
harbouring HPV16 or HPV18.
Prediagnostic seropositivity for HPV raised the risk to develop
cervical carcinoma only for those carcinomas that contained the
same type of viral DNA. An exception to this was HPV33 seropo-
sitivity that was associated with an increased risk to develop
HPV16 DNA-carrying carcinomas. There are several possible
reasons for this ﬁnding, notably (i) chance, (ii) cross-induction
of HPV33-speciﬁc antibodies by infection with the closely related
HPV16 and (iii) a biological interaction whereby previous
HPV33 infection promotes the oncogenicity of HPV 16. The fact
that a similar tendency for HPV33 to increase the cervical carcino-
ma risk together with HPV16 has been noted before (Silins et al,
1999) suggests that the phenomenon is not merely due to chance.
HPV serology has high speciﬁcity for sexually transmitted HPV
types, since HPV seropositivity is rare among virginal or monoga-
mous women (af Geijerstam et al, 1999). However, a series of
validation studies have concluded that only about 50–70% of geni-
tally infected women (as determined by PCR) will seroconvert
(Kirnbauer et al, 1994; Carter et al, 1996; Kjellberg et al, 1999).
The reason why HPV serology is not very sensitive for detection
of HPV infection is not known. In the present study only 26 out
of 72 (36%) of women with HPV16 DNA-positive carcinomas
had prediagnostic HPV16 seropositivity and only 5 out of 19
(26%) of women with HPV18 DNA-positive carcinomas had
prediagnostic HPV18 seropositivity. There are several possible
reasons why the sensitivity was particularly low in our study. There
was a long time-lag between drawing of the serum sample and the
occurrence of the carcinoma and some women may have acquired
their infection after the drawing of the serum sample. The serum
samples had been stored at 7208C for up to 20 years and although
IgG is generally stable on storage, the possibility that there may
have been some decay on prolonged storage can not be excluded.
There were a few cases with no HPV DNA in tumour. This
could represent false negative HPV DNA tests due to old tissue
samples or samples of bad quality. Since most of the HPV infec-
tions are transient (Hildesheim et al, 1994; Evander et al, 1995;
Ho et al, 1998), another possibility is that after the infections with
HPV 16, 18 and/or 33 have ceased, a history of HPV infection may
still increase the risk for cervical carcinoma. However, as seroposi-
tive women were not at increased risk to develop carcinomas that
were HPV-negative or containing other types of virus, our data
strongly suggests that persistent type-speciﬁc HPV infection is
required and that the HPV DNA-negative cases either really are
HPV-negative or contain unknown HPV types that are not
adequately ampliﬁed by the PCR tests used.
In conclusion, this study advances previous prospective epide-
miological studies of HPV and cervical carcinoma by providing
improved case deﬁnition with reclassiﬁed histological diagnoses
and by providing a within-study evaluation of the sensitivity of
HPV serology, enabling correction of the relative risk estimates
for misclassiﬁcation. Furthermore, the ﬁnding that prediagnostic
seropositivity only increases risk for development of carcinomas
with the same type of HPV DNA in the tumour further supports
the view that the role of HPV infection in cervical carcinoma is
mediated via persistent type-speciﬁc HPV infection.
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